Pharmaceutical

Emergent to sell US sterile manufacturing facility to Bora

Emergent BioSolutions has agreed to divest its sterile manufacturing facility in Baltimore-Camden, Maryland, to Bora Pharmaceuticals.

Jun 22, 2024 - 04:00
Emergent to sell US sterile manufacturing facility to Bora
Emergent BioSolutions has agreed to divest its sterile manufacturing facility in Baltimore-Camden, Maryland, to Bora Pharmaceuticals.
Read the original article

Tags:

Previous Article

South Korea seeks to accelerate drug reimbursement administration process

Next Article

Johnson & Johnson seeks FDA approval for Tremfya for Crohn’s disease

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

J&J seeks expanded approvals for paediatric HIV-1 therapy

J&J seeks expanded approvals for paediatric HIV-1 therapy

Jun 6, 2024

These are the need-to-know biotech stories from this weekend

These are the need-to-know biotech stories from this we...

Nov 13, 2023

STAT+: British Columbia to bar Americans from buying Ozempic over supply concerns

STAT+: British Columbia to bar Americans from buying Oz...

Mar 30, 2023